Argos HIV Immunotherapy Offers Potential Reprieve From Antiretrovirals
This article was originally published in The Pink Sheet Daily
Executive Summary
Through automation and economies of scale, Argos believes its personalized HIV immunotherapy can be "cost competitive with current therapies" with a dosing scheme that offers freedom from ART regimens.